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3972 | J. Mater. Chem. B, 2013, 1, 39Trans-diﬀerentiation of human mesenchymal stem cells
generates functional hepatospheres on poly(L-lactic
acid)-co-poly(3-caprolactone)/collagen nanoﬁbrous
scaﬀolds†
Dillip Kumar Bishi,abc Santosh Mathapati,abc Jayarama Reddy Venugopal,*a
Soma Guhathakurta,d Kotturathu Mammen Cherian,b Seeram Ramakrishnaa
and Rama Shanker Verma*c
Mesenchymal stem cell (MSC)-based liver tissue engineering on nanoﬁbrous scaﬀold holds great promise
for cell-based therapy in liver injuries and end-stage liver failure treatments. We investigated the
hepatic trans-diﬀerentiation potential of human MSCs on a biocomposite poly(L-lactic acid)-co-poly
(3-caprolactone)/collagen (PLACL/collagen) nanoﬁbrous scaﬀold. The nanoﬁbrous scaﬀolds comprised of
PLACL, collagen and a PLACL/collagen blend (2 : 1) were fabricated by electrospinning and also
evaluated for ﬁber morphology, surface wettability, functional groups, porosity and tensile properties.
Hepatic trans-diﬀerentiation of human bone marrow-derived MSCs (hMSCs) was carried out on these
scaﬀolds over a period of 28 days using sequential induction with hepatogenic growth factors.
Hepatogenesis was conﬁrmed by scanning electron microscopy (SEM), cell phenotype tracking dye
expression, quantitative expression of hepatic genes, immunoﬂuorescence staining of hepatocyte-speciﬁc
markers and albumin release. The results proved that the porous PLACL/collagen nanoﬁbrous scaﬀold
supported enhanced hMSC proliferation and hepatic trans-diﬀerentiation compared to individual PLACL
and collagen scaﬀolds as well as a monolayer culture on tissue culture plate (TCP). Interestingly, hMSC-
derived hepatocyte-like cells on PLACL/collagen nanoﬁbrous scaﬀolds could aggregate to form
functional ‘hepatospheres’ similar to normal hepatic spheroids. The present study concludes that PLACL/
collagen nanoﬁbrous scaﬀolds are potentially biomimetic and upon sequential induction with
hepatogenic growth factors/cytokines, it augments trans-diﬀerentiation of hMSCs towards functional
hepatosphere formation. Such bioengineered nanoﬁbrous scaﬀold hepatic construct provides a
promising approach for cellular therapy of damaged livers in end-stage liver failure treatments.Introduction
The liver, the organwith the highest regenerative potential, cannot
replenish its damaged hepatocytes in patients with end-stage liver
failure, and liver transplantation is the only alternative. However,
the growing demand for liver homogras for transplantation is ontory, Nanoscience and Nanotechnology
al University of Singapore, Singapore.
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nd Vascular Diseases, Frontier Lifeline,
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nanobrous scaﬀolds. See DOI:
72–3984the rise due to the shortage of organ donors and gra incompati-
bility.1 Regeneration of the liver tissue by potential hepatogenic
precursor cells isa therapeutic possibility, provided theymimic the
functionality of native hepatocytes in the liver microenvironment.
Stemcells of varying stemness and tissueorigin suchas embryonic
stem cells,2 hematopoietic stem cells,3 induced pluripotent stem
cells,4 adipose tissue-derived stemcells5 and cordblood stemcells6
have been proven as promising candidates for hepatocyte diﬀer-
entiation. Embryonic stem cells (ESCs), being pluripotent, possess
the highest hepatogenic diﬀerentiation potential, but controver-
sies related to teratoma formation, immune rejection and ethics
involved in deriving them limit their therapeutic roles.7,8 Bone
marrow-derivedMSCs, though comparatively less plastic, can give
rise to functional hepatocytes9 and if injected in an autologous
manner can serve as the best therapeutically eﬀective cell source
for treating liver failure.
As clinical transplantation of MSCs for liver tissue regener-
ation becomes a promising tool, an ideal hepatic tissueThis journal is ª The Royal Society of Chemistry 2013



























































































View Article Onlineengineering strategy needs to be optimized before the in vitro
regenerated tissue or organ can be taken from bench to bedside.
In this regard, MSCs have been explored for ne-tuned trans-
diﬀerentiation towards hepatic lineages, with a dened milieu
of chemicals and growth factors in a sequential manner, of
course, on extracellular matrix (ECM) scaﬀolds.10 Growth
factors in combination with ECM enhance the attachment,
proliferation and diﬀerentiation of stem cells, thus mimicking
the in vivo microenvironment.11 Most of the studies investi-
gating MSC diﬀerentiation to hepatocytes have been performed
on monolayer cultures.9,12 However, such methodologies result
in ineﬃcient and heterogenous diﬀerentiation, as the two-
dimensional (2D) cultures do not mimic the natural liver
microenvironment. Three-dimensional (3D) culture systems
support an eﬀective and homogenous diﬀerentiation by
providing structural integrity, promoting improved cell–cell and
cell–ECM interactions due to high surface area and porosity
thus ensuring growing hepatic tissue remodelling.13,14 The fate
of MSCs during diﬀerentiation is known to be modulated by
nanotopographical cues.15 In fact, hepatocytes, because of their
anchorage dependence, proliferate better on 3D nanobrous
scaﬀolds and form functional aggregates.16,17
Electrospinning is a simple and potentially eﬀective meth-
odology that has successfully delivered fabrication of nano-
brous structures of micro- to nanoscale dimensions
comparable to those of natural ECM.18 These electrospun
nanobrous scaﬀolds possess high volume-to-surface areas and
porosity, thus facilitating eﬀective cell–cell and cell–ECM
communications and 3D tissue regeneration. A variety of
biodegradable and biocompatible polymers of natural and
synthetic origins have been employed to fabricate nanobrous
scaﬀolds for tissue engineering applications. Biosynthetic
hybrid scaﬀolds that provide suitable biological and mechan-
ical features and mimic the ECM architecture of liver tissue can
be used as a suitable substrate for hepatic tissue engineering.
PLACL is a synthetic, biodegradable and non-toxic copolymer of
poly-L-lactic acid (PLLA) and polycaprolactone (PCL), which has
been widely studied as a biomaterial for surgery and drug
delivery applications.19 On blending with collagen, this copoly-
mer becomes preferable for various tissue engineering appli-
cations, as collagen possess unique integrin binding sites on its
surface for cell adhesion and proliferation.20,21 Stem cells have
been diﬀerentiated towards hepatocyte-like cells eﬀectively on
various nanobrillar surfaces in a proof-of-concept style.22–26
However, optimization is still needed to modulate stem cell
diﬀerentiation towards generation of a functional 3D hepatic
construct on nanobrous scaﬀolds. In the present study, we
have attempted to evaluate the in vitro hepatomimetic potential
of a well-established biosynthetic nanobrous scaﬀold fabri-
cated from a PLACL and collagen blend (2 : 1) by inducing
hepatic trans-diﬀerentiation of human bone marrow MSCs.
This study focused on assessing the impact of 3D biosynthetic
nanobrous scaﬀolds from a PLACL/collagen blend upon
hepatic trans-diﬀerentiation of hMSCs as compared to indi-
vidual PLACL and collagen nanobrous scaﬀolds as well as a
conventional monolayer culture system on tissue culture
plate (TCP).This journal is ª The Royal Society of Chemistry 2013Experimental section
Materials
For diﬀerentiation experiments, hMSCs were acquired from
Lonza (Allendale, NJ, USA). Poly(L-lactic acid)-co-poly-(3-capro-
lactone) (70 : 30, Mw 150 kDa) was obtained from Boehringer
Ingelheim Pharma, GmbH & Co., Ingelheim, Germany. Dul-
becco's modied Eagle's medium (DMEM), fetal bovine serum
(FBS), antibiotics and trypsin–EDTA, CMFDA (5-chloromethyl-
uorescein diacetate), secondary antibody Alexa Fluor 488 and
594, Iscove's modied Dulbecco's medium (IMDM), TRIzol
reagent, SuperScript rst strand synthesis system and 40-6-
diamidino-2-phenylindole (DAPI) were procured from Invi-
trogen (Life Technologies, Carlsbad, CA, USA). Bovine serum
albumin (BSA), 1,1,1,3,3,3-hexauor-2-propanol (HFP), anti-
human anti-albumin antibody raised in goat, anti-CY-18, anti-
AFP, hexamethyldisilazane (HMDS), hepatocyte growth factor
(HGF), oncostatin M (OSM), insulin-transferring selenium
premix (ITS), dexamethasone, nicotinamide, epidermal growth
factor (EGF) and basic broblast growth factor (bFGF) were
from Sigma-Aldrich (St. Louis, MO, USA). Collagen type I was
obtained from Koken Company Ltd. (Tokushima-ku, Tokyo,
Japan). SYBR green real-time PCR mastermix was purchased
from Applied Biosystems (Foster City, CA, USA).Fabrication of electrospun nanobrous scaﬀolds
Polymer solutions of PLACL (10%, w/v), collagen (8% w/v) and a
PLACL/collagen blend (10% w/v, 2 : 1 w/w ratio) were prepared
by dissolving them in HFP. For electrospinning, the respective
polymer solutions were fed into a 3 ml standard syringe
attached to a blunted stainless steel needle (22½ G) using a
syringe pump (KD-100, KD Scientic Inc., Holliston, MA, USA)
at an optimized ow rate of 1 ml h1. On application of a high
voltage (Gamma High Voltage Research, Ormond Beach, FL,
USA) of 18.5 kV, the polymer solution was spun as nanobers of
random orientation, which were collected on coverslips (diam-
eter, 15 mm; thickness, 0.13–0.16 mm, Menzel-Glaser, Thermo
Scientic, Germany). The ambient conditions of the spinning
apparatus were controlled with a vacuum dehumidier
machine (KNF Neuberger Inc, Trenton, NJ, USA). The nanober
mats spun on the cover slips were dried overnight in vacuum to
remove the residual solvents and subsequently used for char-
acterization and cell culture experiments.Characterization of nanobrous scaﬀolds
The morphology of electrospun nanobers on coverslips was
examined under a eld emission scanning electron microscope
(FESEM) (FEI-QUANTA 200F, The Netherlands) at an acceler-
ating voltage of 10 kV, aer sputter-coating with gold (JEOL JFC-
1200 ne coater, Japan). The average diameter of the nanobers
was determined by measuring at 100 diﬀerent points in 512 
471 pixel scanning electron microscopic (SEM) images (with a
scale of 9.6 pixels per mm) using image analysis soware
(ImageJ, National Institutes of Health, Bethesda, MD, USA). The
wettability of the nanobrous scaﬀolds was measured by sessile
drop-water contact angle measurement using a VCA OptimaJ. Mater. Chem. B, 2013, 1, 3972–3984 | 3973



























































































View Article OnlineSurface Analysis system (AST products, Billerica, MA). The
hydrophobic PLACL nanobrous scaﬀolds were made hydro-
philic by air plasma treatment with electrodeless radio
frequency glow discharge plasma cleaner (Model: PDC-001,
Harrick Scientic Corporation, USA). Attenuated total reec-
tance Fourier transform infrared (ATR-FTIR) spectroscopic
analysis of electrospun nanobrous scaﬀolds was performed on
an Avatar 380 instrument, (Thermo Nicolet, Waltham, MA, USA)
over a range of 450–4500 cm1 at a resolution of 2 cm1.
Porosity as well as pore size distribution of the nanobrous
scaﬀolds was measured by a capillary ow porometer (CFP-
1200-A, Ithaca, NY, USA) by wet up/dry up method and the
analysis was done using automated capillary ow porometer
system soware. The thickness of PLACL, collagen and PLACL/
collagen nanobrous scaﬀolds were measured by a micrometer
(Mitutoyo, Japan) and their apparent density and porosity were
calculated according to He et al.27 Tensile properties of elec-
trospun nanobrous scaﬀolds were determined with a tabletop
tensile tester (Instron 3345, Canton, MA, USA). Initially, the
electrospun membrane mat of 20–30 mm thickness was cut into
rectangular specimens of 10 mm (breadth)  20 mm (length)
dimensions. The specimen ends were gripped with the clips of
tensile testing machines and with an applied load (10 N) via
automated soware (Bluehill 2 Materials Testing Soware for
Universal Testing Systems, Norwood, MA, USA) at a crosshead
speed of 5 mm min1, and the data were recorded every 50 ms.
The generated tensile stress–strain curve data was calculated to
nd out the tensile stress–strain and elastic modulus of the
nanobrous scaﬀolds. A minimum of six specimens of indi-
vidual scaﬀolds of PLACL, collagen and PLACL/collagen
membranes having equal length, breadth and thickness were
analysed for the tensile strength measurements.
Culture and maintenance of hMSCs on nanobrous scaﬀolds
Cryopreserved hMSCs of passage 2 were revived and cultured in
DMEM–high glucose medium supplemented with 10% FBS, 1%
antibiotic and antimycotic solution under humidied condi-
tions of 37 C and 5% CO2. Cells were maintained till they
reached conuence and fresh culture medium was replenished
twice per week. Meanwhile, the coverslips coated with nano-
brous scaﬀolds were subjected to UV sterilization for 3 h and
were placed in 24-well tissue culture plates with a stainless steel
ring placed over them to prevent the scaﬀold liing oﬀ the glass
coverslips. The scaﬀolds were washed thrice with phosphate-
buﬀered saline (PBS) to remove any residual cytotoxic solvent
and soaked in DMEM overnight before cell seeding. Conuent
hMSCs were detached by 0.25% trypsin–EDTA and seeded on
the scaﬀolds (PLACL, collagen and PLACL/collagen) as well as
on TCP at a density of 1  104 cells per cm2. The cell–scaﬀold
constructs were maintained under standard culture conditions
before initiating the hepatic trans-diﬀerentiation experiments.
Hepatic trans-diﬀerentiation protocol
Hepatic trans-diﬀerentiation of hMSCs was performed by
sequential exposure to a cocktail of inducers9 aer 70–80%
conuence on the various scaﬀolds and TCP. The cells were3974 | J. Mater. Chem. B, 2013, 1, 3972–3984serum-deprived for 2 days and placed in IMDM supplemented
with 20ngml1 EGFand10ngml1 bFGF, prior to inductionby a
two-step protocol. These preconditioned cells were treated with
step 1 diﬀerentiation medium, consisting of IMDM supple-
mented with 20 ng ml1 HGF and 10 ng ml1 bFGF, 0.61 g L1
nicotinamide for 7 days, followed by step 2maturationmedium,
consisting of IMDM supplemented with 20 ng ml1 oncostatin
M, 1 mmol L1 dexamethasone, and 50 mg ml1 insulin–trans-
ferrin–selenium (ITS+) premix. The diﬀerentiating cells were
maintained in a standard humidied atmosphere for up to 28
days and replenished with fresh diﬀerentiation/maturation
media twice per week. The extent of hepatogenesis was assessed
on the 14th and 28th days by observing the morphological
changes, hepatic marker expression and functional assays.
Cell proliferation
The hMSC proliferation rates on various nanobrous scaﬀolds
and TCP during hepatic diﬀerentiation were evaluated at the
7th, 14th and 28th days using colorimetric MTS assay (CellTiter
96 Aqueous One solution, Promega, Madison, WI). The assay is
based on the principle that mitochondrial dehydrogenase
enzymes of metabolically active cells reduce the yellow tetra-
zolium salt [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2(4-sulfophenyl)-2H-tetrazolium] in MTS reagent to
form purple formazan crystals and the amount of crystals
formed is directly proportional to the number of live cells. In
this experiment, cells were rinsed with PBS and incubated for 3
h in a 1 : 5 ratio mixture of MTS reagent and serum-free DMEM
medium. Aer the incubation period, the samples were pipetted
out into 96-well plates and the absorbance was measured at 490
nm using a microplate reader (Fluostar Optima, BMG Lab
Technologies, Germany).
Cell phenotype tracking by uorescent dye expression
The phenotypic changes of the hMSCs during the process of
hepatic diﬀerentiation were tracked using the uorescent dye
CMFDA, which on cleavage of its acetates by cytosolic esterases
produces a brightly uorescent CMFDA derivative. At various
time points (7th day onwards until the 28th day), the diﬀerenti-
ating cells were incubated with fresh DMEM medium contain-
ing 25 mM CMFDA dye. Aer incubation, the cells were
replenished with fresh culture medium and incubated over-
night. Next day, the cells were washed with PBS in the dark and
observed under an inverted Leica DM IRB laser scanning
microscope (Leica DC 300F) at 488 nm.
Cell morphology analysis by scanning electron microscopy
Cell attachment, proliferation and morphological changes of
the diﬀerentiating hMSCs on the nanobrous scaﬀolds as well
as on TCP were analysed on the 7th and 28th days by SEM. The
cells were xed in 3% glutaraldehyde for 3 h followed by
washing in deionized water and dehydration with upgrading
concentrations of ethanol (50%, 70% 90%, 100%) twice for 15
min each. The nal washing with 100% ethanol was followed by
air-drying with hexamethyldisilazane (HMDS) overnight in a
fume hood. The cell–scaﬀold constructs on the coverslips wereThis journal is ª The Royal Society of Chemistry 2013



























































































View Article Onlinesputter-coated with gold and the morphologies of undiﬀeren-
tiated and diﬀerentiated cells were scanned under FESEM at an
accelerating voltage of 10 kV.
Immunouorescence staining for hepatic marker expression
Hepatocyte specic marker expression in trans-diﬀerentiated
hMSCs cultured on diﬀerent substrates aer the 28th day of
induction was analysed by immunouorescence. The cells were
xed with 100% ice-cold methanol for 10 min and per-
meabilized with 0.1% Triton-X 100. To avoid non-specic anti-
body binding, cells were blocked with 3% BSA followed by
incubation with mouse monoclonal primary antibody for
human albumin (ALB)/a-fetoprotein (AFP)/cytokeratin-18 (CY-
18) (1 : 100) overnight at 4 C. The cells were washed thrice and
incubated with Alexa Fluor 488 and 594 (1 : 250) for 1 h and the
nuclei were stained with DAPI (0.5 mg ml1) for another 30 min.
The cells were nally washed and mounted on a glass slide with
Vectashield (Vector Laboratories, Burlingame, CA, USA) and
uorescent marker expression was observed under a laser
confocal scanning microscope (Olympus FV1000).
RNA isolation, semi-quantitative reverse transcription
polymerase reaction (RT-PCR) and quantitative real-time RT-
PCR for hepatic gene expression
Total RNA was isolated from hMSCs diﬀerentiated in various
substrates as well as the control group on days 14 and 28 using
TRIzol reagent and the quality and quantity of RNA were
measured with a Nanodrop spectrophotometer (Nanodrop
Technologies, Wilmington, DE, USA). The total RNA isolated
from an equal number of untreated hMSCs was used as a
negative control and that of HepG2 cells as the positive control
in this experiment. All RNA samples (10 mg) were treated with
DNase-I and rst-strand cDNA synthesis was carried out with
random hexamers using the SuperScript rst-strand synthesis
system according to the manufacturer's protocol. Semi-quanti-
tative RT-PCR for early hepatic genes such as AFP, hepatocyte
nuclear factor-4a (HNF-4a) and late hepatic gene ALB was
carried out by amplifying the cDNA with specic primers (Table
2) under optimised thermal cycling conditions. The amplied
products were separated by electrophoresis on a 1.2% agarose
gel and stained with ethidium bromide for visualization.
Quantitative real-time PCR for hepatic genes (AFP, ALB and
HNF-4a) was carried out with ABI PRISM 7500 Fast Real-Time
PCR System using SYBR green master mix. The experiment was
optimized with the addition of 10 ml of 2 SYBR Green PCR
Master Mix, 30 ng template cDNA and 5 pmol forward and
reverse primers, in a total volume of 25 ml for a total of 40 cycles
at an annealing temperature of 60 C. Melting curve analysis
was performed at the end of the reaction to determine the
melting temperature (Tm) of a single nucleic acid target
sequence in an unknown sample. Relative quantication of
gene expression in unknown samples was performed using the
comparative CT (2
DDCT) method by normalizing with a refer-
ence gene (glyceraldehyde-3-phosphate dehydrogenase) and
untreated MSCs of third passage were used as the calibrator. All
reactions were performed in triplicate for statistical validation.This journal is ª The Royal Society of Chemistry 2013Albumin ELISA
To evaluate the functionality of the hMSCs-derived hepatocytes
on various substrates, we assessed the amount of albumin
secreted into the culturemedia at various time points (days 7, 14,
21 and 28). HepG2 conditioned media prepared by culturing an
equal number HepG2 cells as the number of hMSCs used for the
diﬀerentiation experiment was used as a positive control.
Albumin secretion was determined using a human albumin
ELISA quantitation set (Bethyl Laboratory, Montgomery, TX,
USA) according to the manufacturer's instructions. Briey, the
wells of an ELISA plate were coated with aﬃnity-puried human
albumin coating antibody for 1 h followed by blocking for 30
min. Each standard (serially diluted), control and sample were
loaded into the wells and incubated for 1 h followed by the
addition of a HRP-conjugated human albumin detection anti-
body. Tetramethylbenzidine (TMB) substrate solutionwasadded
for 15 min and color reaction was stopped by the stop solution
(0.16Msulfuric acid). Absorbancewasmeasured at 450nmusing
a microplate reader (Fluostar Optima, BMG Lab Technologies,
Germany). The amount of albumin released was normalised to
the total number of cells determined from each well.Statistical analysis
All the experiments were done in triplicate for statistical vali-
dation and reproducibility was assessed by repeating each
experiment at least thrice. The diﬀerences in hMSC prolifera-
tion rate and hepatic gene expression as well as albumin release
during the process of diﬀerentiation on various scaﬀolds were
compared and the average value represented as mean  stan-
dard deviation (SD). Statistical diﬀerences within and between
the groups were analysed using one- or two-way analysis of
variance (ANOVA) followed by Tukey's post hoc test with
statistical package for social sciences (IBM SPSS statistics,
version 19, NY, USA). Diﬀerences were considered statistically
signicant at p # 0.05.Results
Characterization of electrospun nanobrous scaﬀolds
The optimised process of electrospinning generated nano-
brous scaﬀolds (PLACL, collagen and PLACL/collagen blend)
with uniform, bead-free, randomly oriented bers of unpat-
terned topography and interconnected pores. The SEM images
of the nanobers revealed an average ber diameter of 563.58
21.89, 283  12.68 and 352  16.28 nm for PLACL, collagen and
PLACL/collagen, respectively (Fig. 1). The bers (>60%) are of
nanoscale dimensions, mostly in the range 200–600 nm.
Hydrophilicity studies of the scaﬀolds by water contact angle
measurement (Table 1) shows that PLACL was initially highly
hydrophobic, and was made hydrophilic by plasma treatment.
The collagen and PLACL/collagen nanobrous scaﬀolds were
adsorbent, revealing the presence of hydrophilic groups on
their surfaces.
The ATR-FTIR spectra of nanobrous scaﬀolds reveals chem-
ical characteristics and functional groupspresent on their surface
that are responsible for their hydrophilicity. The PLACL/collagenJ. Mater. Chem. B, 2013, 1, 3972–3984 | 3975
Fig. 1 FESEM images of electrospun nanoﬁbers of PLACL (A), collagen (B) and a PLACL/collagen blend (C) at high magniﬁcation (5000) showing unpatterned
topography with their respective size distributions (D–F).
















PLACL 129.3  2.8 1.98  0.64 88.92  12.16 1.02  0.44 1.24 654.82 83  12
52.6  9.6a
PLACL/Collagen 46.7  5.5 0.52  0.12 50.29  19.28 0.88  0.28 0.58 354.47 89  16
a Aer plasma treatment.
Table 2 The genes and primer sequences used in RT-PCR and real-time PCR
Gene namea Primer sequence (50–30) Product size (bp) NCBI accession number
ALB F: TGAGAAAACGCCAGTAAGTGAC 265 NM_000477.5
R: TGCGAAATCATCCATAACAGC
ALB* F: CGCTATTAGTTCGTTACACCA 101 NM_000477.5
R: TTTACAACATTTGCTGCCCA
AFP F: GCTTGGTGGTGGTGGATGAAACA 157 NM_001134.1
R: TCCTCTGTTATTTGTGGCTTTTG
AFP* F: AAATGCGTTTCTCGTTGC 136 NM_001134.1
R: GCCACACGGCCAATAGTTTGT
HNF 4a F: GAGCAGGAATGGGAAGAATG 205 NM_000457.3
R: GGCTGTCCTTTGGGATGAAG
HNF 4a* F: ATGACAATGAGTATGCCTACCT 131 NM_178850.1
R: GGTCGTTGATGTAGTCCTCC
GAPDH* F: GCACCGTCAAGGCTGAGAAC 73 NM_002046.3
R: GGATCTCGCTCCTGGAAGATG
b-ACT F: AGAGCTACGAGCTGCCTGAC 184 NM_001101.2
R: AGCACTGTGTTGGCGTACAG
a F: forward primer; R: reverse primer; ALB: albumin; AFP: a-fetoprotein; HNF 4a: hepatocyte nuclear factor 4a; GAPDH: glyceraldehyde-3-
phosphate dehydrogenase; b-ACT: b-actin. * denotes primers used in real time PCR.



























































































View Article Onlinenanobrous scaﬀold shows characteristic absorption peaks
common to PLACL alone along with unique peaks at 3287 cm1
and 3018 cm1, representing an N–H stretch of amide A (AA) and
C–Hstretchof amideB (AB), respectively, suggesting thepresence3976 | J. Mater. Chem. B, 2013, 1, 3972–3984of amino groups on their surfaces (Fig. 2). Peaks at 1649 and
1550 cm1 for amide I (AI) and amide II (AII) bands represent
collagen's secondary structure and the peak at 1287 cm1 for
amide III (AIII) represents the triple helical structure of collagen.This journal is ª The Royal Society of Chemistry 2013
Fig. 2 FT-IR spectra of PLACL and PLACL/collagen nanoﬁbers with peaks representing speciﬁc functional groups (AA: amide A; AB: amide B; AI: amide I, AII: amide II
and AIII: amide III).



























































































View Article OnlineThe pore size distributions as well as the average pore size of the
PLACL/collagen nanobrous scaﬀold shows varying porosity as
detailed inTable 1.Mechanical strengthmeasurements of PLACL
and PLACL/collagen nanobrous scaﬀolds showed a typical
stress–strain curve (Fig. S1, ESI†) and three zones could be
distinguished. In therst zone, stress increasednon-linearlywith
strain (up to 5% strain). In the second zone, stress increased
linearlywith strain (between5%and45%strain) andnally in the
third zone (aer 45% strain) deformation was observed. The
modulus of elasticity was determined from the linear part of the
curve. Other tensile parameters are given in Table 1. The tensile
properties of PLACL/collagen (2 : 1) blended nanobrous scaf-
folds were lower than that of PLACL. The elastic modulus of the
PLACL/collagen nanobrous scaﬀolds was comparable to that of
PLACL nanobrous scaﬀolds.Fig. 3 MTS assay for hMSCs proliferation on nanoﬁbrous scaﬀolds of PLACL,
collagen, PLACL/collagen and TCP during hepatic diﬀerentiation. The diﬀerences
in cell number within the groups are signiﬁcant between TCP and collagen, TCP
and PLACL/collagen, PLACL and collagen and PLACL and TCP at D7 and D14 (*p#
0.05). The cell numbers in TCP, PLACL, collagen and PLACL/collagen nanoﬁbrous
scaﬀolds show an increase when comparing between D7 vs. D14 and D7 vs. D28
(**p # 0.05). No signiﬁcant increase in cell number was observed during hepatic
maturation on any of nanoﬁbrous scaﬀolds except TCP at day 28 compared to day
14 (#p # 0.05).Proliferation of hMSCs
MTS assay results showed that there was a signicant increase
in hMSC proliferation ( p # 0.05) on collagen and PLACL/
collagen nanobrous scaﬀolds compared to PLACL and TCP
aer 7 days of culture (Fig. 3). This indicates that the initial cell
attachment and cell–scaﬀold interactions were better on
collagen and PLACL/collagen. The cell number increased
signicantly on all the scaﬀolds at day 14 and also on day 28
compared to day 7. Additionally, increases within the group
appear to be statistically signicant between TCP and collagen,
and TCP and PLACL/collagen at D7 and D14. SEM analysis of
hMSCs seeded on various nanobrous scaﬀolds on day 7 reveals
eﬀective cell–scaﬀold interactions and spreading with higher
eﬃciency on collagen and PLACL/collagen compared to PLACL
(Fig. 4). Although, higher cell proliferation was observed onThis journal is ª The Royal Society of Chemistry 2013PLACL/collagen and collagen scaﬀolds at day 14 compared to
other substrates, no further increase in proliferation was
observed at day 28. Interestingly, there was no signicant
diﬀerence in cell growth between PLACL/collagen and collagen
scaﬀolds at diﬀerent time points. On the other hand, a signi-
cant increase in cell number ( p# 0.05) was observed on TCP at
day 28 compared to day 14. PLACL scaﬀolds were comparablyJ. Mater. Chem. B, 2013, 1, 3972–3984 | 3977
Fig. 4 FESEMmicrographs showing hMSCs adhesion and growth after 7 days of
culture on TCP (A), PLACL (B), collagen (C) and PLACL/collagen nanoﬁbrous
scaﬀolds (D) at 1000 magniﬁcation. Interaction of hMSCs with nanoﬁbers
allowed better adhesion and proliferation on collagen and PLACL/collagen
nanoﬁbrous scaﬀolds.



























































































View Article Onlineless supportive for cell attachment and proliferation at various
time points.
Hepatic trans-diﬀerentiation of hMSCs
During hepatic diﬀerentiation, it was observed that the
spindle-shaped broblastic morphology of hMSCs was main-
tained during initial cell spreading as well as the pre-
conditioning step in the rst week. However, the morphology
had changed aer 7 days of hepatic induction and they
possessed broad, attened morphologies with a high nucleo-
cytoplasmic ratio. Upon further maturation with oncostatin M,
dexamethasone and ITS premix for two more weeks up to dayFig. 5 FESEM micrographs showing hMSCs-derived hepatocyte-like cells at day 2
dimensions on PLACL/collagen nanoﬁbrous scaﬀolds (D) at 1000 magniﬁcation.
nanoﬁbrous scaﬀolds are of diﬀerent size, approximately 50 mm (E) to 95 mm diame
PLACL/collagen nanoﬁbrous scaﬀolds for hepatic trans-diﬀerentiation to form hep
diameters, whereas the white dotted arrow in (E) indicates the excessive ECM pro
indicates hepatocyte-like cells formed on the collagen nanoﬁbrous scaﬀolds.
3978 | J. Mater. Chem. B, 2013, 1, 3972–398428, the diﬀerentiated cells acquired cuboidal to polygonal
shape (Fig. 5A–C) with accumulations of abundant cyto-
plasmic granules. On collagen scaﬀolds, the hMSC-derived
hepatocyte-like cells acquired polygonal shapes (Fig. 5C) as of
normal hepatocytes, whereas the extent of diﬀerentiation was
less on PLACL, which showed a at irregular morphology
(Fig. 5B) aer 28 days of diﬀerentiation. TCP supported
minimal diﬀerentiation potential with few proliferating
hMSCs still retaining the spindle shaped morphology
(Fig. 5A). Interestingly, the diﬀerentiating hMSCs on PLACL/
collagen nanobrous scaﬀolds accumulated to form spheroid-
like aggregates as happens in hepatocyte primary cultures on
3D culture system.17 The hepatospheres thus formed (5  2
per cm2 area) are evenly distributed (Fig. 5D) and are of
diﬀerent sizes with a range of 10–100 mm diameter (Fig. 5D–F)
as assessed by ImageJ analysis soware. Such spheroids are
associated with higher cellular metabolism, which correlates
with the 28 day MTS assay data of the PLACL/collagen nano-
brous scaﬀolds. The hepatospheres formed on this scaﬀold
very eﬀectively with proper integration with the scaﬀold
matrix, and abundant secretion of ECM components was quite
evident (Fig. 5E). Phenotypical changes during hepatic diﬀer-
entiation tracked by CMFDA uorescent dye expression reveal
a noticeable diﬀerence in the cellular morphology on the
PLACL/collagen nanobrous scaﬀold. Until day 7, the hMSCs
maintained a spindle-shaped broblastic morphology and
then acquired a at, polygonal morphology on day 18, with
retracting ends. On day 21 of induction, the diﬀerentiating
cells started aggregating, only on the PLACL/collagen nano-
brous scaﬀolds, with a spheroid-like morphology being
prominent on day 24. Fully formed hepatospheres were
observed on day 28 with more cells accumulating to form
spheroids (Fig. 6).8 on TCP (A), PLACL (B) and collagen (C) as well as hepatospheres of diﬀerent
Representative micrographs showing hepatospheres formed on PLACL/collagen
ter (F) at 2500 and 1000magniﬁcation respectively. hMSCs adapted better on
atospheres. The white arrows in (D and F) represents hepatospheres of diﬀerent
teins secreted by hepatospheres spread over nanoﬁbers. The black arrow in (C)
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Fig. 6 CMFDA ﬂuorescent dye expression in trans-diﬀerentiating hMSCs on PLACL/collagen nanoﬁbrous scaﬀolds depicting phenotypic progress in hepatosphere
formation. Fluorescent micrographs show an undiﬀerentiated ﬁbroblastic morphology on day 7 (A), a cuboidal morphology on day 14 (B) and day 18 (C), cell migration
on day 21 (D), aggregate formation on day 24 (E) and mature hepatosphere formation on day 28 (F) (scale bar ¼ 200 mm).



























































































View Article OnlineSemi-quantitative and quantitative expression of hepatic
genes
Positive expression of AFP, HNF-4a and ALB at days 14 and 28 on
various substrates at the mRNA level validates the trans-diﬀer-
entiation of hMSCs towards a hepatic lineage (Fig. 7). Semi-
quantitativeRT-PCR results reveal that the expressionof ALBand
HNF-4a was greater on day 28 compared to day 14, whereas AFP
expression remained either same or declined aer day 14 during
the process of diﬀerentiation (Fig. 7A). Diﬀerentiation on PLACLFig. 7 Hepatocyte-speciﬁc gene expression proﬁle of hMSCs-derived hepatocyte
quantiﬁcation of a-fetoprotein, HNF-4a and albumin mRNA expression by RT-PCR (B
hMSCs were used as a negative control, whereas HepG2 cells were used as a positive
groups were statistically signiﬁcant at p # 0.05.
This journal is ª The Royal Society of Chemistry 2013scaﬀolds was characterized by the low level of expression of all
three hepatic genes on both day 14 and 28 compared to other
scaﬀolds. The untreated MSCs did not express any of hepatic
genes. Quantitative real-time PCR analysis of hMSCs diﬀerenti-
ated on various scaﬀolds at day 14 showed a higher level of AFP,
HNF-4a and ALB expression on PLACL/collagen nanobrous
scaﬀolds compared to other substrates (Fig. 7B–D). The expres-
sion level of HNF-4a and ALB gradually increased from day 14 to
28, whereas AFP expression declined signicantly ( p # 0.05) at-like cells/hepatospheres by semi-quantitative RT-PCR analysis (A) and relative
, C and D respectively) on various scaﬀolds and TCP on days 14 and 28. Untreated
control for hepatic gene expression. Diﬀerences in gene expression between the
J. Mater. Chem. B, 2013, 1, 3972–3984 | 3979
Fig. 8 Confocal microscopy images (merged) showing expression of hepatocyte speciﬁc markers, AFP (Alexa ﬂuor 594: red colour), ALB (Alexa ﬂuor 488: green colour)
and CY-18 (FITC: green colour) for hepatocyte-like cells formed on TCP, PLACL and collagen and hepatospheres formed on PLACL/collagen nanoﬁbrous scaﬀolds at day
28. Nuclei were stained with DAPI (blue colour). Three dimensional hepatospheres on PLACL/collagen nanoﬁbrous scaﬀolds showed strong expression of albumin and
cytokeratin-18 and weak expression of a-fetoprotein (scale bar ¼ 20 mm).



























































































View Article Onlineday 28 compared to day 14 on PLACL/collagen nanobrous
scaﬀolds (Fig. 7B). However, there was no signicant decline in
AFP expression ( p # 0.05) aer day 14 in trans-diﬀerentiated
hepatocyte-like cells on TCP, PLACL and collagen scaﬀolds. Also,
there was a signicant diﬀerence ( p # 0.05) in hepatic gene
expression between hepatocyte-like cells on collagen and hep-
atospheres on PLACL/collagen at day 28. The quantitative
expression of all three genes by hepatospheres formed on
PLACL/collagen at day 28 was comparable to that of HepG2 cells.
Immunouorescence analysis of hepatic markers
The trans-diﬀerentiation eﬃciency of hMSCs to hepatocytes was
further conrmed by immunouorescence staining for theFig. 9 Confocal microscopy images (merged) for AFP expression (Alexa Fluor 59
scaﬀolds on day 14 (A), day 18 (B), day 21 (C), day 24 (D) and day 28 (E). Nuclei w
expression was observed on hepatospheres at day 28 (scale bar ¼ 20 mm).
3980 | J. Mater. Chem. B, 2013, 1, 3972–3984expression of hepatocyte-specic markers AFP, ALB and CY-18
protein levels at day 28 (Fig. 8). Cells induced to diﬀerentiate
into hepatocytes on PLACL/collagen and collagen scaﬀolds
showed enhanced uorescent expression of all three markers
compared to cells on PLACL scaﬀolds and TCP. The three
dimensional hepatospheres formed on the PLACL/collagen
nanobrous scaﬀolds showed a higher expression of albumin
and cytokeratin-18, whereas the expression of AFP was down-
regulated at day 28. We assessed the expression pattern of AFP
on the PLACL/collagen nanobrous scaﬀolds to trace its down-
regulation with the progress of maturation during hepato-
sphere formation. On day 14, the expression of AFP was stron-
gest and as maturation progressed, AFP expression declined4: red colour) during hepatosphere formation on PLACL/collagen nanoﬁbrous
ere stained with DAPI (blue colour). A decline in ﬂuorescence intensity for AFP
This journal is ª The Royal Society of Chemistry 2013
Fig. 10 Albumin assay for culture media collected during hepatic trans-diﬀer-
entiation of hMSCs on various substrates and TCP at diﬀerent time points. HepG2
conditioned medium was used as a positive control which was independent of
substrate parameters as well as time points. The diﬀerences in albumin concen-
tration within the groups were signiﬁcant between TCP and collagen, TCP and
PLACL/collagen, collagen and PLACL/collagen at day 28 (*p # 0.05). No signiﬁ-
cant increase in albumin release was observed between days 21 and 28 on TCP,
PLACL and collagen nanoﬁbrous scaﬀolds (**p # 0.05). However, hepatospheres
on PLACL/collagen nanoﬁbrous scaﬀolds showed a higher amount of albumin
release at day 28 compared to days 14 and 21.



























































































View Article Onlinewith hepatosphere formation on day 28 (Fig. 9) which correlates
with the quantitative real time gene expression data.
Functional assay of the trans-diﬀerentiated hepatocytes on
nanobrous scaﬀolds
The amount of albumin released into the culture media was
negligible on day 7 and increased as diﬀerentiation progressed.
The amount of albumin secretion was signicantly higher on day
28 ( p # 0.05) on all substrates compared to day 14 and day 21
(Fig. 10). Diﬀerences in albumin concentration were observed
between TCP vs. collagen and TCP vs. PLACL/collagen at days 14,
21 and 28. Although there was no diﬀerence in albumin release
from hepatocyte-like cells on collagen and PLACL/collagen at day
21 ( p ¼ 0.605), the hepatospheres formed on PLACL/collagen at
day 28 released more albumin ( p # 0.05) compared to the
collagen scaﬀolds as well as TCP and PLACL. No signicant
increase in albumin release was observed between day 21 and 28
on TCP, PLACL and collagen scaﬀolds. The progressive increase
in albumin concentration is in accordance with real-time PCR
data and is higher on the PLACL/collagen nanobrous scaﬀolds
onday 28compared toother timepoints.UntreatedMSCsshowed
a negligible amount of albumin release. Albumin released from
day 28 hepatospheres on PLACL/collagen nanobrous scaﬀolds
was comparable to that of HepG2 cells ( p ¼ 0.081).
Discussion
An ideal strategy for stem cells and nanotechnology based liver
tissue engineering would involve suitable biocompatible scaf-
folds, an eﬀective stem cell source and a hepatomimetic
microenvironment. Electrospun nanobrous scaﬀolds haveThis journal is ª The Royal Society of Chemistry 2013proven to be eﬀective in providing nanotopographical signals,
mechanical stability, structural guidance and anchorage for cell
integration with the surrounding tissues.18 MSCs, due to their
easy accessibility and possible trans-diﬀerentiation potential
towards hepatocytes,9,12 serve as a prospective cell source for
liver tissue engineering. Piryaei et al.24 have successfully diﬀer-
entiatedmouse bonemarrow-derivedMSCs into hepatocyte-like
cells on ultra-web nanobers (Ultra-Web Synthetic ECM;
Donaldson Co., Minneapolis, MN, USA). Kazemnejad et al.22
could derive hepatocyte-like cells from hMSCs on a biocom-
patible nanobrous scaﬀolds. Most of these studies report the
generation of hepatocyte-like cells on electrospun nanobrous
scaﬀolds, but failed to achieve functional 3D hepatic aggre-
gates, similar to those observed with normal hepatocytes on
nanobrous scaﬀolds. We have reported for the rst time the
generation of hMSCs-derived functional 3D hepatospheres on
electrospun nanobrous scaﬀolds.
The present study evaluated the hepatic trans-diﬀerentiation
potential of hMSCs seeded on electrospun nanobrous scaf-
folds of a PLACL/collagen blend (2 : 1) by sequential induction
with hepatogenic growth factors. Bioengineered scaﬀolds
should be suﬃciently hydrophilic to allow superior cell adhe-
sion, spreading and inltration similar to that of the native
hepatic microenvironment, which is highly hydrated. Initially,
PLACL was strongly hydrophobic, but blending it with collagen
impregnated functional groups such as amine, hydroxyl and
carboxyl groups to its surface to make it more hydrophilic for
liver tissue engineering. FTIR analysis of PLACL/collagen
reveals the presence of unique peaks of collagen representing
amides A and B as well as amides I, II and III apart from
common PLACL peaks (Fig. 2). This implies that blending a
collagen component with PLACL enhances the bioactivity of the
composite scaﬀolds, as it greatly favours cell adhesion and
proliferation. Porosity of the scaﬀold is an important parameter
for hepatic tissue engineering and PLACL/collagen nanobrous
scaﬀolds with porosities as high as 89% with maximum pore
distribution allows proper cell attachment and inltration, easy
ow of nutrients, metabolites, hepatogenic growth factors and
waste products in and out of cells, which is desirable for a liver
tissue construct. The tensile properties of the nanobrous
scaﬀolds are an important attribute, while considering its in
vivo implantation as a hepatic substitute. The mechanical
stability of the substrate plays an important role, as the scaﬀold
guides the growth, proliferation and diﬀerentiation of stem
cells. Low stiﬀness may be a desirable property of the scaﬀolds
with regard to integration with native tissue, since an extremely
stiﬀ matrix might hinder the proliferation and diﬀerentiation
potential of stem cells. Ideally, less stiﬀ and biodegradable
scaﬀolds such as PLACL and collagen are better choices for
generating tissue engineered hepatic constructs in vitro. In the
present study, PLACL/collagen (2 : 1) scaﬀolds possess
adequate tensile properties to withstand a stress of 0.52  0.12
MPa and a strain of 50.29 19.28% at maximum load (Table 1).
The elastic modulus, which is a measure of resistance to
deformation (stiﬀness), was around 0.88 MPa for the PLACL/
collagen nanobrous scaﬀolds, whereas that of normal liver
tissue is below 10 kPa.28 Therefore, for engineering so tissuesJ. Mater. Chem. B, 2013, 1, 3972–3984 | 3981



























































































View Article Onlinelike liver, the stiﬀness needs to be controlled to guide eﬀective
diﬀerentiation of hMSCs on scaﬀolds. PLACL/collagen nano-
brous scaﬀolds, being highly porous and biodegradable,
might be eﬀective in maintaining low stiﬀness upon implan-
tation, which needs further assessment.
With regard to initial cell adhesion and proliferation, the
PLACL/collagen and collagen scaﬀolds provided a supportive
microenvironment and there was an increase in cell number at
day 7 as well as at increasing time points. Since the hMSCs
adapted better to the scaﬀolds, cell number increased at day 14
and also on day 28 compared to day 7. The increase in cell
number within the group between TCP and collagen, and TCP
and PLACL/collagen at D7 and D14 may be due to the initial cell
adhesion to the extracellular matrix (ECM) that is mediated by
an integrin transmembrane receptor present in the collagen
component.20 However, since the cells started diﬀerentiating,
no signicant increase in cell number was observed between
day 14 and 28 cultures ( p # 0.05) on collagen and PLACL/
collagen nanobrous scaﬀolds. The increase in cell number
from day 14 to 28 on TCP shows that the hMSCs still retained
stemness and continued proliferation up to day 28 (Fig. 3). This
implies that TCP was not supportive enough for diﬀerentiation.
No signicant diﬀerence in cell growth between the PLACL/
collagen and collagen scaﬀolds at diﬀerent time points implies
that the PLACL/collagen bio-synthetic hybrid scaﬀolds were
supportive enough for cell attachment, proliferation and
diﬀerentiation to mimic natural polymers.
Hepatogenesis of hMSCs was achieved successfully on
various nanobrous scaﬀolds. On day 28, the cells attained
complete diﬀerentiation on various scaﬀolds as evaluated by the
morphological changes, hepatocyte-specic gene expression,
immunouorescence studies of hepatic markers and albumin
release proles. The extent of hepatogenesis is maximal on
PLACL/collagen nanobrous scaﬀolds compared to other
nanobrous scaﬀolds and TCP on day 28 and most importantly
they could form functional hepatospheres, as would normal
hepatocytes on nanobrous scaﬀolds.17 The type of scaﬀold
being employed for cell-based tissue engineering has a
substantial eﬀect upon the morphology of the cells.29 Hepato-
cytes are anchorage-dependent and their interactions with the
ECM nanobrous scaﬀolds induced them to attach and prolif-
erate to form spheroids.30 Physical signals exerted by the nano-
bers in terms of cell–substrate adhesion strength (Fig. 4) are
known to induce directional migration as well as aggregate
formation (Fig. 6) of hepatocytes.17,31 Formation of hepato-
spheres only on the PLACL/collagen-blended scaﬀolds and not
on other nanobrous scaﬀolds of PLACL or collagen (Fig. 5) may
bedue to the suitableber diameter, porosity, long-termstability
of the cell–matrix interactions and guided trans-diﬀerentiation.
PLACL scaﬀolds are not supportive enough for initial cell adhe-
sion and hence diﬀerentiation. Although collagen nanobrous
scaﬀolds possess the best features to allow cell proliferation and
hepatic diﬀerentiation, its weak mechanical prole does not
support hepatosphere formation, rather formingat hepatocyte-
like cells (Fig. 5C). Hepatocyte spheroids are 3D aggregates
that exhibit a high degree of cell–cell contact, biomatrix depo-
sition and hence long-term maintenance with enhanced liver3982 | J. Mater. Chem. B, 2013, 1, 3972–3984function.32,33 Cells in spheroids also have a morphology and
ultra-structure similar to those found in a native liver lobule.34
The hMSCs-derived hepatospheres evidently showed superior
hepatic features such as increased expression of mature hepatic
genes and proteins (HNF-4a and ALB) and albumin secretion in
culture media, compared to the hepatocyte-like cells formed on
other nanobrous scaﬀolds and TCP. The quantitative expres-
sion of all hepatic genes in hepatospheres was comparable to
that of HepG2 cells, which implies that hepatospheres are
functional entities. Although thenumber of positive cellswasnot
countable due to technical diﬃculties with the nanobers,
apparently most of the cells contributed towards hepatosphere
formation, as demonstrated by SEM (Fig. 5D) and immunou-
orescence studies (Fig. 8). However, it is yet to be ascertained
whether the majority of the cells within hepatospheres are
indeed mature functional hepatocytes. Expression of the AFP
gene as well as proteins declined on day 28 in the hepatosphere
as compared to hepatocyte-like cells on day 14 (Fig. 7B and 9),
which is a feature of diﬀerentiating hepatocytes which happens
during normal liver development.35 This implies that the PLACL/
collagen nanobrous scaﬀolds support the hepatocyte diﬀeren-
tiation process. Another important feature for appropriate
hepatic functionality is the size of the hepatosphere; if it is below
100 mm, the cells in the interior of the spheroids do not become
hypoxic.13,36 The hMSC-derived hepatospheres formed on the
PLACL/collagen nanobrous scaﬀolds are in the range 10–100
mm and hence can be appropriate hepatic constructs for further
studies on in vivo liver tissue engineering. Also, hepatocytes
grown on 2D monolayers tend to de-diﬀerentiate rapidly losing
their liver specic functions37 and hence a 3D spheroid culture is
suggested to be eﬀective in preventing de-diﬀerentiation.38
Hepatospheres derived from hMSC trans-diﬀerentiation in this
study show appropriate functional attributes such as albumin
secretion and 3D spheroid formation. Due to the unique
biodegradation proles of the PLACL and collagen components
of the biocomposite PLACL/collagen nanobrous scaﬀolds, such
bioengineered hepatic construct is expected to integrate easily
with the host tissue upon implantation, which can be conrmed
only aer in vivo animal studies. However, the central mecha-
nism elucidating the possible role of nanotopographical cues in
guiding cellular remodelling and migration to form hepato-
spheres needs to be investigated further at a molecular level,
particularly the formation of focal adhesions of hMSCs by
nanobers. It is known that the nanobrous scaﬀolds due to its
topographical stimuli promotes appropriate adhesion and
structural remodelling to the growing hMSCs by forming focal
adhesions39 and provides a tissue mimicking microenviron-
ment. However, the role of soluble growth factors ismore critical
in augmenting hepatic trans-diﬀerentiation of hMSCs. There-
fore, the synergistic eﬀects of the biomaterial-based nanobers
(physical cues) and the optimized chemical soluble factors
(humoral cues) improved the eﬃciency of trans-diﬀerentiation
of hMSCs in this study. Recent studies suggest that the orienta-
tions or diameters of the nanobers40 and surface charges41 are
also crucial factors for regulating the function of cells resulting
in controlled cell shapes. The observed results from the PLACL/
collagen nanobers with random orientation and averageThis journal is ª The Royal Society of Chemistry 2013



























































































View Article Onlinedimensions at a nano- to microscale (mostly of 200–600 nm
diameter), promotes adhesion, migration and spheroid forma-
tion during hepatic trans-diﬀerentiation of hMSCs.Conclusion
A tissue-engineered strategy for hepatic regeneration was the
goal of the study, wherein hMSCs could be modulated to form
functional hepatospheres on PLACL/collagen (2 : 1 blend)
nanobrous scaﬀolds with greater eﬃcacy. The present study
conrms the PLACL/collagen nanobrous scaﬀolds augments
trans-diﬀerentiation of hMSCs towards the generation of 3D
hepatic constructs. The superior hepatic trans-diﬀerentiation
potential of hMSCs on this blended biosynthetic composite may
be attributed to the biophysical signals provided by the nano-
structures and the mechanism involved needs further evalua-
tion. Such an in vitro bioengineered hepatic construct might be
a potential tool for future applications in hepatotoxicity testing,
cellular therapy for end-stage liver failure and the development
of tissue-engineered bioarticial liver, aer addressing the long
term maintenance of functionality in animal studies.Acknowledgements
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